Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996, for The Female Health Company, Inc. (formerly Wisconsin Pharmacal Company, Inc.). The Company is a developer and marketer of the female condom ("Reality"). During the period, the Company completed a major strategic restructuring: it sold its "Holdings" subsidiary (leisure and institutional health care segments) on January 29, 1996, and acquired Chartex International, PLC (the manufacturer and IP owner of the female condom) on February 1, 1996. Consequently, the Company now operates solely in the female health sector with global manufacturing capabilities.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1996 | Six Months Ended Mar 31, 1996 |
|---|---|---|
| Net Revenues | $263,561 | $730,508 |
| Net Loss | $(1,981,071) | $(2,443,953) |
| Loss Per Share (Diluted) | $(0.31) | $(0.38) |
| Cash and Cash Equivalents (End of Period) | $1,357,150 | |
| Net Cash Used in Operating Activities (6 Months) | $(3,275,376) | |
| Total Current Liabilities | $5,797,685 | |
| Inventory (Net) | $2,919,965 |
Note: The Company recorded a $300,000 charge for inventory obsolescence in the quarter. Gross margin was negative ($398,005 loss) for the quarter due to this charge and high trade discounts.
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 38% ($162,873) for the quarter and 26% ($252,394) for the six months compared to the prior year. This was driven by reduced marketing spend due to capital constraints and a shift in sales mix toward lower-priced public sector sales.
- Discontinued Operations: The Company reclassified the "Holdings" segment as discontinued. While the prior year included significant losses from this segment, the current period reflects only a nominal loss of $4,461 on the sale of Holdings.
- Elimination of Exclusivity Fees: The Company ceased accruing "Reality exclusivity fees" (which totaled $869,746 in the prior year quarter) following the acquisition of Chartex, which eliminated the licensing agreement.
- Expense Structure: General and administrative expenses increased significantly ($578,457 for the quarter) due to the inclusion of Chartex's operations and depreciation/amortization of newly acquired assets. Conversely, selling expenses decreased by $476,601 due to reduced marketing budgets.
Guidance, Outlook, and Risks
Liquidity and Capital Needs: The Company faces a critical liquidity situation. Management estimates a need to source approximately $2.0 million within four months and a cumulative $8.1 million by March 31, 1997 to fund operations, debt repayments, and marketing. Without this capital, the Company may be forced to cease operations or sell assets.
Planned Funding Sources:
- Refinancing the Chartex manufacturing facility (up to $2.7 million).
- U.K. Regional Selective Assistance Program grant (up to $768,000, contingent on employment goals).
- Working capital credit facility (up to $0.6 million).
- Sales of Common Stock (approximately $6.0 million).
Operational Outlook: The Company estimates it must sell approximately 18.8 million female condoms worldwide at an average price of $1.00 to break even on a cash basis. A new marketing campaign launched in March 1996 showed early promise, with April 1996 revenues increasing 88% over April 1995.
Risks and Contingencies:
- Contingent Liabilities: The Company remains contingently liable for approximately $4.7 million in obligations (leases and employment agreements) of the sold "Holdings" subsidiary if the buyer fails to pay.
- Product Acceptance: Sales have been substantially lower than expectations. Viability depends on increased consumer acceptance and successful global launches (e.g., Japan expected late 1996/early 1997).
- Key Personnel: Operations are heavily dependent on the services of the CEO and President.
Investor Verification Checklist
- Verify the status of the $8.1 million capital raise required for the next 12 months, specifically the refinancing of the Chartex facility and the U.K. grant approval.
- Confirm the contingent liability exposure regarding the sale of WPC Holdings (approx. $4.7 million) and the buyer's ability to meet obligations.
- Monitor inventory levels ($2.9 million) and the risk of further write-downs if sales do not accelerate.
- Assess the progress of the Japanese regulatory approval and the launch timeline, as this is a key growth driver.
- Review the April 1996 revenue increase (88% vs. prior year) to determine if the new marketing campaign is sustainable.